Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.9M | $20.6M | $38.0M | $89.1M | $101.2M | $144.4M | $120.2M | $102.8M |
| Cost of revenue | $13.2M | $19.7M | $25.1M | $47.0M | $69.6M | $95.4M | $82.4M | $76.1M |
| Gross profit | $791.0K | $833.0K | $12.9M | $42.1M | $31.6M | $49.0M | $37.8M | $26.7M |
| Gross margin | 5.7% | 4.1% | 34.0% | 47.2% | 31.2% | 34.0% | 31.4% | 26.0% |
| R&D | $24.5M | $60.6M | $76.8M | $119.9M | $84.4M | $75.9M | $80.2M | $51.8M |
| Operating income | −$50.7M | −$85.7M | −$110.0M | −$126.8M | −$119.5M | −$123.7M | −$115.0M | −$69.9M |
| EBITDA | −$49.8M | −$84.1M | −$121.5M | −$112.3M | −$115.8M | −$132.3M | −$104.6M | −$72.4M |
| Net income | −$50.6M | −$87.7M | −$131.2M | −$117.4M | −$125.5M | −$148.4M | −$194.3M | −$99.0M |
| Net margin | -362.9% | -426.8% | -344.8% | -131.8% | -124.0% | -102.8% | -161.7% | -96.3% |
| EPS (diluted) | -21.77 | -41.51 | -45.06 | -36.40 | -33.90 | -34.89 | -37.39 | -15.13 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds ATNX.
No tracked institution reports a position in ATNX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-02-15 | 1-for-20reverse |
No one on the platform has traded ATNX yet.
| $12M |
| — |
| NTBLNotable Labs, Ltd. | $0.25 | -27.68% | $2M | — |
| PLXPPLx Pharma Inc. | $0.09 | +0.00% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.